Cargando…

Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment

PURPOSE: This study aims to investigate the association between paternal methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T) and embryonic development, pregnancy, and neonatal outcomes in intracytoplasmic sperm injection (ICSI) treatment. METHODS: A total of 191 infertile men undergoin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Yangyang, Liu, Wenjing, Xu, Bo, Jiang, Xiaohua, Hua, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816894/
https://www.ncbi.nlm.nih.gov/pubmed/36619555
http://dx.doi.org/10.3389/fendo.2022.1084463
_version_ 1784864643430219776
author Wan, Yangyang
Liu, Wenjing
Xu, Bo
Jiang, Xiaohua
Hua, Juan
author_facet Wan, Yangyang
Liu, Wenjing
Xu, Bo
Jiang, Xiaohua
Hua, Juan
author_sort Wan, Yangyang
collection PubMed
description PURPOSE: This study aims to investigate the association between paternal methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T) and embryonic development, pregnancy, and neonatal outcomes in intracytoplasmic sperm injection (ICSI) treatment. METHODS: A total of 191 infertile men undergoing ICSI treatment at the Reproductive and Genetic Hospital, The First Affiliated Hospital of USTC, were recruited between January 2020 and June 2021. The MTHFR C677T polymorphism genotyping was evaluated in these male patients, and they were stratified into three groups according to genotyping results: Control (CC), heterozygote mutated (CT), and mutated homozygote (TT). In addition, we conducted a comparative analysis of embryonic development, pregnancy, and neonatal outcomes among these three groups. RESULTS: The embryonic development (including normal fertilization rate (80.14% vs. 83.06% vs. 85.10%; p = 0.37), high-quality embryo rate (45.26% vs. 43.69% vs. 46.04%; p = 0.72), blastocyst formation rate (42.47% vs. 43.18% vs. 39.38%; p = 0.62), implantation rate (42.47% vs. 36.25% vs. 41.22%; p = 0.62), and clinical pregnancy rate (64.71% vs. 58.75% vs. 66.67%; p = 0.59) were not comparable among these three groups. Moreover, no significant difference was observed in terms of pregnancy outcomes (including miscarriage rate (24.24% vs. 12.77% vs. 22.5%; p = 0.35) and live birth rate (49.02% vs. 51.25% vs. 51.66%; p = 0.96)). Additionally, no marked difference was observed in terms of neonatal outcome (including, preterm delivery rate (24% vs. 14.63% vs. 9.67%; p = 0.35), birth height (p = 0.75), birth weight (p = 0.35), neonatal sex (p = 0.48), gestational age at delivery (p = 0.24), Apgar score (p = 0.34), and birth defects (0% vs. 2% vs. 9%; p = 0.23) among the study groups. CONCLUSION: The paternal MTHFR C677T polymorphism is not associated with embryo quality, pregnancy, or neonatal outcomes in ICSI treatment. Therefore, in our population, MTHFR polymorphisms do not provide helpful information in explaining ICSI failure.
format Online
Article
Text
id pubmed-9816894
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98168942023-01-07 Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment Wan, Yangyang Liu, Wenjing Xu, Bo Jiang, Xiaohua Hua, Juan Front Endocrinol (Lausanne) Endocrinology PURPOSE: This study aims to investigate the association between paternal methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T) and embryonic development, pregnancy, and neonatal outcomes in intracytoplasmic sperm injection (ICSI) treatment. METHODS: A total of 191 infertile men undergoing ICSI treatment at the Reproductive and Genetic Hospital, The First Affiliated Hospital of USTC, were recruited between January 2020 and June 2021. The MTHFR C677T polymorphism genotyping was evaluated in these male patients, and they were stratified into three groups according to genotyping results: Control (CC), heterozygote mutated (CT), and mutated homozygote (TT). In addition, we conducted a comparative analysis of embryonic development, pregnancy, and neonatal outcomes among these three groups. RESULTS: The embryonic development (including normal fertilization rate (80.14% vs. 83.06% vs. 85.10%; p = 0.37), high-quality embryo rate (45.26% vs. 43.69% vs. 46.04%; p = 0.72), blastocyst formation rate (42.47% vs. 43.18% vs. 39.38%; p = 0.62), implantation rate (42.47% vs. 36.25% vs. 41.22%; p = 0.62), and clinical pregnancy rate (64.71% vs. 58.75% vs. 66.67%; p = 0.59) were not comparable among these three groups. Moreover, no significant difference was observed in terms of pregnancy outcomes (including miscarriage rate (24.24% vs. 12.77% vs. 22.5%; p = 0.35) and live birth rate (49.02% vs. 51.25% vs. 51.66%; p = 0.96)). Additionally, no marked difference was observed in terms of neonatal outcome (including, preterm delivery rate (24% vs. 14.63% vs. 9.67%; p = 0.35), birth height (p = 0.75), birth weight (p = 0.35), neonatal sex (p = 0.48), gestational age at delivery (p = 0.24), Apgar score (p = 0.34), and birth defects (0% vs. 2% vs. 9%; p = 0.23) among the study groups. CONCLUSION: The paternal MTHFR C677T polymorphism is not associated with embryo quality, pregnancy, or neonatal outcomes in ICSI treatment. Therefore, in our population, MTHFR polymorphisms do not provide helpful information in explaining ICSI failure. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9816894/ /pubmed/36619555 http://dx.doi.org/10.3389/fendo.2022.1084463 Text en Copyright © 2022 Wan, Liu, Xu, Jiang and Hua https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wan, Yangyang
Liu, Wenjing
Xu, Bo
Jiang, Xiaohua
Hua, Juan
Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment
title Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment
title_full Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment
title_fullStr Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment
title_full_unstemmed Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment
title_short Association of paternal MTHFR polymorphisms (C677T) with clinical outcomes in ICSI treatment
title_sort association of paternal mthfr polymorphisms (c677t) with clinical outcomes in icsi treatment
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816894/
https://www.ncbi.nlm.nih.gov/pubmed/36619555
http://dx.doi.org/10.3389/fendo.2022.1084463
work_keys_str_mv AT wanyangyang associationofpaternalmthfrpolymorphismsc677twithclinicaloutcomesinicsitreatment
AT liuwenjing associationofpaternalmthfrpolymorphismsc677twithclinicaloutcomesinicsitreatment
AT xubo associationofpaternalmthfrpolymorphismsc677twithclinicaloutcomesinicsitreatment
AT jiangxiaohua associationofpaternalmthfrpolymorphismsc677twithclinicaloutcomesinicsitreatment
AT huajuan associationofpaternalmthfrpolymorphismsc677twithclinicaloutcomesinicsitreatment